Table 2—

Effects of ambroxol on trypsin-like protease activity, pulmonary surfactant (SP-A) and mucus protease inhibitor (MPI) in bronchoalveolar lavage fluid of mice with sham infection

Regulatory factorDose of ambroxol mg·kg−1·day−1Days after virus infection
01234567
Trypsin-like protease activity µU·mL−1025.0±2.025.0±1.820.0±1.520.0±5.025.0±6.025.0±8.020.0±10.025.0±8.0
1026.7±3.030.0±10.033.4±1.6*55.0±16.0*50.0±13.0*20.0±9.125.0±10.0
3026.7±2.433.4±18.040.0±11.0*60.0±22.0*25.0±10.020.0±7.720.0±6.0
SP-A ng·mL−102.2±0.32.4±0.82.7±1.12.4±1.02.7±0.92.3±0.72.7±0.82.5±1.0
103.0±0.93.4±1.14.3±2.25.6±1.4*6.8±3.0*6.2±2.2*7.4±3.1*
303.9±1.75.2±1.0*5.6±1.9*8.3±1.2*7.2±3.1*6.9±2.8*6.6±2.1*
MPI µU·mL−10112.5±30.0125.0±26.0130.0±50.0167.0±40.0200.0±98.0130.0±32.0200.0±50.0165.0±50.0
10150.0±40.0200.0±50.0250.0±60.0300.0±50.0500.0±70.0*470.8±50.0*430.0±100.0*
30200.0±60.0250.0±70.0458.5±60.0*550.0±80.0*500.0±60.0*250.0±80.0167.0±70.0
  • The data are presented as means±sd unless otherwise stated, (n=5) at each time point

  • *: p<0.05 between control and ambroxol